Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity... Show more
A.I.dvisor indicates that over the last year, MAZE has been loosely correlated with AVXL. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MAZE jumps, then AVXL could also see price increases.
| Ticker / NAME | Correlation To MAZE | 1D Price Change % | ||
|---|---|---|---|---|
| MAZE | 100% | -3.75% | ||
| AVXL - MAZE | 45% Loosely correlated | -1.99% | ||
| VKTX - MAZE | 41% Loosely correlated | -5.96% | ||
| IMNM - MAZE | 37% Loosely correlated | -8.20% | ||
| ADMA - MAZE | 35% Loosely correlated | +1.28% | ||
| KYTX - MAZE | 31% Poorly correlated | -7.09% | ||
More | ||||
Industry Biotechnology
The Moving Average Convergence Divergence (MACD) for MAZE turned positive on September 22, 2026. Looking at past instances where MAZE's MACD turned positive, the stock continued to rise in 10 of 11 cases over the following month. The odds of a continued upward trend are 90%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MAZE's RSI Oscillator exited the oversold zone, 4 of 5 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +7.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where MAZE advanced for three days, in 89 of 101 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 14 of 19 cases where MAZE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MAZE as a result. In 26 of 32 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
MAZE moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MAZE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
MAZE broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MAZE entered a downward trend on September 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. MAZE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.292) is normal, around the industry mean (26.782). MAZE has a moderately high P/E Ratio (191.339) as compared to the industry average of (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (63.291) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MAZE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.